← Leaderboards
Stefan M. Pulst
Utah State Higher Education System--University Of Utah
$18,000,219
Attributed
$20,369,989
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,500,003 · 16
CDC$869,986 · 1
By mechanism
R35$3,693,093 · 1
R37$3,588,694 · 1
R01$3,107,557 · 2
U01$2,793,983 · 2
P50$2,440,711 · 1
R21$2,044,954 · 5
Top collaborators
- Daniel R Scoles11 shared
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Daniel R Scoles$6,542,278
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesProteinsAffectCellsPhenotypeIn VivoNeuronsMutantIn VitroPolyglutaminePurkinje CellsNeurodegenerative DisordersBaseNerve DegenerationAtaxiaMotorPathway InteractionsAllelesMouse ModelInheritedCerebellumBrainSca2 ProteinHuman Disease
Grant awards (52)
Ataxin-2 complex proteins in neurodegeneration.$930,250
R35 · FY2025 · NS · contact PI
Targeting STAU1 for TDP-43 proteinopathies$384,997
R33 · FY2025 · NS
Ataxin-2 complex proteins in neurodegeneration.$902,343
R35 · FY2024 · NS · contact PI
Targeting STAU1 for TDP-43 proteinopathies$384,997
R33 · FY2024 · NS
Ataxin-2 complex proteins in neurodegeneration.$930,250
R35 · FY2023 · NS · contact PI
Ataxin-2 complex proteins in neurodegeneration.$930,250
R35 · FY2022 · NS · contact PI
Targeting STAU1 for TDP-43 proteinopathies$383,748
R61 · FY2022 · NS
Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 2$743,700
U01 · FY2020 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$534,368
R37 · FY2020 · NS · contact PI
Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 2$590,956
U01 · FY2019 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$534,368
R37 · FY2019 · NS · contact PI
Characterization of ATXN2 as a target for ALS in SCA2 motor neurons$228,750
R21 · FY2019 · NS · contact PI
Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 2$589,341
U01 · FY2018 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$534,368
R37 · FY2018 · NS · contact PI
Characterization of ATXN2 as a target for ALS in SCA2 motor neurons$190,625
R21 · FY2018 · NS · contact PI
Deep cerebellar stimulation to treat degenerative cerebellar ataxias$190,625
R21 · FY2018 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$493,335
R37 · FY2017 · NS · contact PI
Deep cerebellar stimulation to treat degenerative cerebellar ataxias$227,500
R21 · FY2017 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$493,335
R37 · FY2016 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$493,335
R37 · FY2015 · NS · contact PI
Comp B-Western Intermountain Regional NMD STARnet$419,993
U01 · FY2015 · DD · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$505,585
R37 · FY2014 · NS · contact PI
Comp B-Western Intermountain Regional NMD STARnet$449,993
U01 · FY2014 · DD · contact PI
Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2$221,265
R21 · FY2014 · NS
Identification of mutation causing Purkinje cell degeneration in the shaker rat$184,388
R21 · FY2014 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$473,383
R56 · FY2013 · NS · contact PI
Identification of mutation causing Purkinje cell degeneration in the shaker rat$223,813
R21 · FY2013 · NS · contact PI
Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2$186,250
R21 · FY2013 · NS
Spinocerebellar Ataxia Type 2 Gene and Gene Product$325,021
R01 · FY2012 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$325,021
R01 · FY2011 · NS · contact PI
Drug Discovery for Spinocerebellar Ataxia Type 2 (SCA2)$834,912
RC4 · FY2010 · NS · contact PI
Parkin Binders in Progression of Cellular Dysfunction and Death$581,160
P50 · FY2010 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$328,337
R01 · FY2010 · NS · contact PI
Parkin Binders in Progression of Cellular Dysfunction and Death$544,464
P50 · FY2009 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$342,701
R01 · FY2009 · NS · contact PI
Parkin Binders in Progression of Cellular Dysfunction and Death$515,882
P50 · FY2008 · NS · contact PI
Spinocerebellar Ataxia Type 2 Gene and Gene Product$329,219
R01 · FY2008 · NS · contact PI
Parkin Binders in Progression of Cellular Dysfunction and Death$527,456
P50 · FY2007 · NS · contact PI
Parkin Binders in Progression of Cellular Dysfunction and Death$271,749
P50 · FY2006 · NS · contact PI
Parkin Interacting Proteins$211,363
R21 · FY2006 · NS · contact PI
Parkin Interacting Proteins$180,375
R21 · FY2005 · NS
SPINOCEREBELLAR ATAXIA TYPE 2 - GENE AND GENE PRODUCT$296,268
R01 · FY2003 · NS
SPINOCEREBELLAR ATAXIA TYPE 2 - GENE AND GENE PRODUCT$30,000
R01 · FY2003 · NS
SPINOCEREBELLAR ATAXIA TYPE 2 - GENE AND GENE PRODUCT$289,155
R01 · FY2002 · NS
SPINOCEREBELLAR ATAXIA TYPE 2 - GENE AND GENE PRODUCT$281,130
R01 · FY2001 · NS
SCA2 GENE AND GENE REPLACEMENT$237,978
M01 · FY2001 · RR
SPINOCEREBELLAR ATAXIA TYPE 2 - GENE AND GENE PRODUCT$272,943
R01 · FY2000 · NS
NF2 BINDING PROTEINS$211,749
R01 · FY2000 · NS
SPINOCEREBELLAR ATAXIA TYPE 2 - GENE AND GENE PRODUCT$76,013
R01 · FY2000 · NS
SCA2 GENE AND GENE REPLACEMENT$982
M01 · FY2000 · RR
SCA2 GENE AND GENE REPLACEMENT$0
M01 · FY2000 · RR
SCA2 GENE AND GENE REPLACEMENT$0
M01 · FY2000 · RR